



## Curriculum Vitae

La sottoscritta dr.ssa Sartori Giulia consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art. 76 del D.P.R. 445/2000, dichiara che le informazioni riportate nel seguente curriculum vitae, redatto in formato europeo, corrispondono a verità.

### Personal information

First name(s) / Surname(s) **GIULIA SARTORI**  
Address(es) **Omissis**  
Telephone(s)  
Fax(es)  
E-mail [sartorigmt@gmail.com](mailto:sartorigmt@gmail.com)  
Nationality Italian  
Date of birth **07/08/1985**  
Gender Female

### Work experience

Date (from-to) From November 2015 to November 2020  
Name and address of employer Department of Medical Oncology, University of Verona (ITALY)  
Director Prof. Giampaolo Tortora, M.D., Ph.D (till October 2018)  
Director Prof. Michele Milella, M.D., Ph.D, (from October 2018)  
Occupation or position held Oncologist Resident Doctor  
Date (from-to) October 2020  
Department of Medical Oncology, University of Verona (ITALY)  
Director Prof. Michele Milella, M.D., Ph.D,  
Occupation or position held Medical Oncologist, PhD student  
Date (from-to) April 2021  
Department of Medical Oncology, Aulss Berica 8  
Occupation or position held Medical Oncologist

### Education and training

Date (from-to) 2007/2008-2013/2014  
Name and type of education training Degree course in Medicine and Surgery at Verona University (ITALY)  
• 2013-2014 Department of Medical Oncology at University of Verona (ITALY),  
Director Prof. G. Tortora, as internal student.

Title of qualification awarded	March 9th, 2015: degree in Medicine and Surgery with Full Marks and Honours (110/110 cum laude) at Verona University (ITALY).
Date (from-to)	<ul style="list-style-type: none"> <li>Experimental thesis "Ruolo prognostico di mutazioni "drivers" determinate mediante metodiche di Next Generation Sequencing, e dell'espressione del gene c-MET in pazienti resecati per neoplasia gastrica". Chairman: Prof. Giampaolo Tortora.</li> </ul> <p>July 2015: Italian Medical License Exam (IMLE) at University of Verona (ITALY). Member of register of Verona Order of Physicians and Surgeons from September 8th, 2015.</p>
Date (from-to)	From November 2015 to November 2020
Name and type of education training	<p>Medical Oncology Residency Department of Medical Oncology, University of Verona (ITALY),          Director Prof. Giampaolo Tortora, M.D., Ph.D (till October 2018)          Director Prof. Michele Milella, M.D., Ph.D, (from October 2018)</p>
Title of qualification awarded	November 24, 2020: Specialistic Degree in Medical Oncology with Full Marks and Honors (70/70 cum laude) at Verona University (ITALY).
<b>Experience-Clinical and basic research experience</b>	<ul style="list-style-type: none"> <li>Experimental thesis "Circulating Biomarkers as Predictors of Immunotherapy outcome in advanced NSCLC".</li> <li>From October 2020 to January 2021. Sub-investigator in 'Aegean' a phase III, double blind , placebo-controlled multicenter International Study for the treatment of Patients with resectable stage II and III NSCLC.</li> <li>May 2020-January2021. Sub-investigator in 'MAURIS', phase IIIB trial in ED Small Cell Lung Cancer.</li> <li>From February 2020-January 2021. Sub-investigator in Rational multicentric, observational and non interventional trial.</li> <li>From February 2020-June 2020. Sub-investigator in Sub-investigator in Be-Pacific, real world trial.</li> <li>From March 2019-June 2020. Sub-investigator in 'INVIDIA 2' observational trial.</li> <li>From March 2019-January 2021. Sub-investigator in CABinMET, phase II single arm study with Cabozantinib in NSCLC.</li> <li>From February 2019-June 2020. Sub-investigator in MDSCs perspective and observational study, in Stage IV NSCLC treated with ICIs.</li> <li>From July 2018-June 2020. Sub-investigator in PACIFIC R, real-world study.</li> <li>From June 2018-June 2020. Sub-investigator in in 'CLDK378A2112' phase I trial.</li> </ul>

**Additional Courses**

Date (from-to)

**Publication  
Personal skills and  
competences**

- From March 6th -8th, ESMO-The Christie Preceptorship on Lung Cancer. Manchester (United Kingdom). Oral presentation: 'Trastuzumab after immunotherapy in a patient affected by an HER-2 mutant advanced lung adenocarcinoma'.
- Avancini A, Tregnago D, Rigatti L, Sartori G, Yang L, Trestini I, Bonaiuto C, Milella M, Pilotto S, Lanza M. Factors Influencing Physical Activity in Cancer Patients During Oncological Treatments: A Qualitative Study. *Integr Cancer Ther.* 2020.
- Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D, Sposito M, Tregnago D, Casali M, Riva ST, **Sartori G**, Menis J, Milella M, Pilotto S. Infections and Immunotherapy in Lung Cancer: A Bad Relationship? *Int J Mol Sci.* 2020.
- Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, **Sartori G**, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. *Lung Cancer.* 2020 Dec; 150:123-131.
- **Sartori G**, Belluomini L, Trovato R, Calìò A, Ugel S, Milella M, Pilotto S. HER2 Aberrations in NSCLC: So Close yet So Far. *JCO Precision Oncology* 2020 :4, 1049-1051
- S Zuliani, I Zampiva, D Tregnago, M Casali, A Cavaliere, A Fumagalli, S Merler, S T Riva, A Rossi, F Zacchi, E Zaninotto, A Auriemma, M Pavarana, C Soldà, L Benini, M Borghesani, A Caldart, S Casalino, Gaule M, D Kadrija, M Mongillo, C Pesoni, P Biondani, S Cingarlini, E Florio, D Melisi, V Parolin, L Tondulli, A Zivi, L Belluomini, C Zecchetto, B Avesani, A Biasi, C Bovo, E Dazzani , A Dodi, S Gelmini, L C Leta, G Lo Cascio, F Lombardo, E Lucin, I A Martinelli, L Messineo, V Moscarda, S Pafumi, A Reni, **G Sartori**, I Scaglione, Y Shoval, M Sposito, E Tacconelli, I Trestini, V Zambonin, S Zanelli, S Pilotto, M Milella. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. *European Journal of Cancer* 2020; 135: 159-169.

	<ul style="list-style-type: none"> <li>• Sartori G, Belluomini L, Lombardo F, Avancini A, Trestini I, Vita E, Tregnago D, Menis J, Bria E, Milella M and Pilotto S. Efficacy and safety of afatinib for non-small cell lung cancer: state-of-the-art and future perspectives. EXPERT REV ANTICANC June 2020.</li> <li>• Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Arduzzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. EUR J CANCER 2020 May; 130: 155-167.</li> <li>• Monteverdi S, Vita E, Sartori G, Ferrara, M, D'Argento E, Tortora, G, Milella M, Bria, E, Pilotto S. Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach? TRANSL CANCER RES 2020 Feb; 9: 409-141.</li> <li>• Avancini A, Sartori G, Gkoutakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, Pilotto S. Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled? ONCOLOGIST 2020 Mar; 25: e555-e569.</li> <li>• Tregnago D, Carbognin L, Trestini I, Avancini A, Sartori G, Fiorio E, Parolin V, Lanza M &amp; Rimondini M, Piccolo L, Bria E, Milella M, Pilotto S. Impact of Cognitive-Behavioral-Therapy (CBT) on levels of anxiety, depression and distress in cancer patients. Annals of Oncology 2019; 30 (suppl_5): v667-v670.</li> <li>• Avancini A, Pala VM, Krogh V, Sieri S, Mariani L, Tregnago D, Sartori G, Trestini I, Bria E, Milella M, Lanza M, Pilotto S. 1833PExercise level, interest and preferences in cancer patients. Annals of Oncology, Volume 30, Issue Supplement_5, October 2019.</li> <li>• Rossi A, Noia VD, Gkoutakos A, D'Argento E, Sartori G, Vita E, Monteverdi S, Lombardo F, Iacovelli R, Carbognin L, Sperduti I, Milella M, Tortora G, Bria E, Pilotto S. PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and metaanalysis. IMMUNOTHERAPY-UK 2019 07; 11: 921-930.</li> <li>• Gkoutakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C, Tortora G, Scarpa A, Bria E, Milella M, Rosell R, Corbo V, Pilotto S. PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. Cancers (Basel) 2019; 11(8): 1141.</li> </ul>
<b>Scientific affiliations</b>	<ul style="list-style-type: none"> <li>• From January 2019: young member of ESMO (European Society of Medical Oncology).</li> <li>• From July 2019: member of AIOM (Associazione Italiana di Oncologia Medica).</li> <li>• From December 2019: young member of IASLC (International Association for the Study of Lung Cancer).</li> </ul>
<b>Mother Language</b>	ITALIAN
<b>Other language(s)</b>	ENGLISH
• Understanding	GOOD
• Writing	GOOD
• Speaking	GOOD
<b>Technical skills and competences</b>	Good knowledge Software: Microsoft Office.
<b>Driving licence</b>	Driving B

I authorize the use of my personal data in accordance with Legal Decree 30 June 2003, No 196 "Protection of personal data" and I assure that the reported information is true.

Verona, 11<sup>th</sup> September 2022

Firma oscurata ai sensi delle Linee Guida del Garante per la Privacy